Pathos Revenue and Competitors

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. \n\nOur patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.